Karyopharm Therapeutics Inc
KPTI6.260USD
+0.170+2.79%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
54.47MValor de mercado
PerdaP/L TTM
Mais detalhes de Karyopharm Therapeutics Inc Empresa
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Informações de Karyopharm Therapeutics Inc
Código da empresaKPTI
Nome da EmpresaKaryopharm Therapeutics Inc
Data de listagemNov 06, 2013
CEOPaulson (Richard A)
Número de funcionários279
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 06
Endereço85 Wells Avenue
CidadeNEWTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02459
Telefone16176580600
Sitehttps://karyopharm.com/
Código da empresaKPTI
Data de listagemNov 06, 2013
CEOPaulson (Richard A)
Executivos da empresa Karyopharm Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
88.34K
+32415.00%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
80.71K
+32415.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
39.66K
+32415.00%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
88.34K
+32415.00%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
80.71K
+32415.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
39.66K
+32415.00%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 31 de jan
Atualizado em: sáb, 31 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
12.58%
Opaleye Management Inc.
5.19%
J. Wood Capital Advisors LLC
4.29%
The Vanguard Group, Inc.
3.06%
Adage Capital Management, L.P.
2.30%
Outro
72.58%
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
12.58%
Opaleye Management Inc.
5.19%
J. Wood Capital Advisors LLC
4.29%
The Vanguard Group, Inc.
3.06%
Adage Capital Management, L.P.
2.30%
Outro
72.58%
Tipos de investidores
Investidores
Proporção
Investment Advisor
18.69%
Hedge Fund
9.85%
Corporation
4.29%
Individual Investor
2.18%
Investment Advisor/Hedge Fund
2.09%
Venture Capital
0.86%
Research Firm
0.66%
Outro
61.38%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
232
6.66M
36.38%
+1.16M
2025Q3
251
4.11M
24.14%
-1.36M
2025Q2
284
4.20M
48.66%
-1.75M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
2023Q3
365
5.88M
77.33%
-1.69M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
T. Rowe Price Investment Management, Inc.
2.30M
13.51%
+1.60M
+228.71%
Oct 31, 2025
Opaleye Management Inc.
949.91K
5.57%
+949.91K
--
Oct 10, 2025
J. Wood Capital Advisors LLC
784.80K
4.6%
+326.67K
+71.30%
Oct 14, 2025
The Vanguard Group, Inc.
408.22K
2.39%
-110.05K
-21.23%
Sep 30, 2025
Adage Capital Management, L.P.
421.32K
2.47%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
183.86K
1.08%
-991.00
-0.54%
Sep 30, 2025
Catalio Capital Management, LP
142.98K
0.84%
-3.03K
-2.07%
Sep 30, 2025
Avidity Partners Management LP
134.57K
0.79%
--
--
Sep 30, 2025
Marshall Wace LLP
128.45K
0.75%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 Covered Call ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Growth ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.01%
Global X Russell 2000 Covered Call ETF
Proporção0%
Invesco NASDAQ Future Gen 200 ETF
Proporção0%
Fidelity Enhanced Small Cap ETF
Proporção0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
iShares Russell 2000 Growth ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Data
Data ex-dividendo
Tipo
Proporção
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
